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Measurement of creatine kinase (EC 2.7.3.2) isoenzyme MB (CK-MB) in serum is still the critical laboratory test in biochemical diagnosis of acute myocardial infarction (AMI)
problems have been identified (3) (4) (5) . Recently, two independent groups of researchers (6, 7) described the use of a unique monoclonal antibody that reacts only to CK-MB, and not with CK-BB, CK-MM, mitochondrial-CK, or iminunoglobulin-bound CK-BB (macro-CK). Incorporating these specific antibodies into an assay allowed for the direct measurement of CK-MB in serum.
The purpose of the present study was to examine the clinical and analytical performance of two commercial immunoassays (Becton Dickinson CK-MB; Ciba-Corning Magic Lite CK-MB) in which a monoclonal anti-CK-MB antibody is used for direct measurement of CK-MB in serum.
MaterIals and Methods

Procedures
For the Becton Dickinson (BD) and Ciba-Corning (Magic Lite) CK-MB assays, we followed the recommended package-insert directions and instrument applications as provided by the manufacturer.
A single lot of reagent was used for each kit for the entire study. The BD assay used in this study has not yet been placed on the market, and our evaluation thus constitutes a premarketing trial. For the BD CK-MB iminunoassay we used the premarketing system essentially described by the manufacturer. In the assay, run in duplicate, a total sample volume of 400 L is used, and it measures the activity concentration. The Ciba-Corning "Magic Lite" CK-MB immunoassay was performed according to the manufacturer's guidelines. The assay, run in duplicate, requires a total sample volume of 200 pL, and it measures mass concentration. For electrophoresis, we used the Ciba-Corning Electrophoresis system (Special Purpose agarose film) essentially as described by the manufacturer. Specimens with total CK activity exceeding 500 U/L were diluted before analysis. The percentage CK-MB multiplied by the total CK activity gives the activity of CK-MB. We measured total CK at 37#{176}C in a Paramax analyzer according to the guidelines of the manufacturer (Baxter 
Patients' Specimens
For patients' specimens, we used serum left over from routine chemistry testing in our hospitals' laboratory. Specimens were collected and stored at -20 #{176}C after review of the patient's medical chart to confirm the clinical diagnosis. The study population consisted of specimens from blood donors (normal subjects), patients clinically diagnosed as having acute myocardial infarction, patients with severe skeletal muscle damage, and other acute and chronically ill patients who did not have any diagnosed myocardial damage. Patients' samples that exceeded linearity were re-analyzed after dilution as suggested by the manufacturers.
Results
Assay Performance
Within-assay and between-assay precision for qualitycontrol material or pooled patients' sera is shown in Table 1 
Patients'Specimens
Normal reference intervals (mean ±2 SD) as determined by use of serum from 50 white adults (25 men, 25 women; ages 20 to 58 y) are shown in Table 2 . One of 50 results was outside the mean ± 2 SD range in both assays. This outlier was a nonathietic, 56-year-old woman with no history of coronary heart disease. Results for CK-MB analyses of serial samples (n = 78) from 10 separate patients with the clinical diagnosis of acute myocardial infarction are summRrized in Table 2 Mean ± 2SD 0-3.4 0-6.0 Range 0-5.5 0-9.9
curves. All three assays exhibited the expected serial CK-MB patterns in all of the 10 patients, as demonstrated in Figure 1 .
Results for CK-MB analyses in serially collected samples (n = 49) from 10 separate patients with the diagnosis of non-AMI-including diabetes, closed head-trauma, drug overdose, splenectomy, bone fractures, renal transplant, endstage liver disease, and hypothermia-are shown in Table 2 . Serum from 28 patients with severe skeletal muscle trauma, such as chest surgery, automobile accidents, stab wounds, rhabdomyolysis, and gunshot wounds were also analyzed for CK-MB by all three methods ( Table 2 ). The poor correlations between electrophoresis and either the BD or Magic Lite assays (Figure 2) exemplify the major problems of CK-MB analysis by electrophoresis in specimens with high total-CK activity. The BD and Magic Lite assays correlated well.
Discussion
Immunoassays used to quantify serum CK-MB that incorporate a monoclonal antibody specific to CK-MB are sensi- tive and specific. Our evaluation of both the BD assay and Magic Lite assay has shown excellent analytical precision (Table 1) and freedom from interferences such as adenylate kinase, macro-CK (CK-BB associated with immunoglobulin), CK-MM, CK-BB, and mitochondrial-CK.
Our data also demonstrate that measurement of CK-MB with these immunoassays correlated extremely well with CK-MB as measured by electrophoresis when utilized in the differential diagnosis of acute myocardial infarction. The sensitivity of these immunoassays in the presence of extremely high CK-MM activities, as in the case of AM! concomitant with severe skeletal muscle irjury, will be of great value in assisting the clinician in the differential diagnosis of AM!.
The analytical precision and lack of interference in both immunoassays (Table 1) agree with other studies (6-8) in which a monoclonal antibody to CK-MB antibody is used to directly measure CK-MB. The BD and Magic Lite CK-MB assays are both easy to perform and results are available within 2 h. The development of a more rapid automated assay would lend itself to a more convenient 24 h per day, seven days per week availability. This would allow laboratories to conveniently provide clinicians with values for both total CK and CK-MB in emergency situations. However, good clinical practice must be maintained, remembering that the serial pattern of the increase and decrease of CK-MB is still the key to the biochemical differential of AMI (Figure 1) (1, 2) .
The BD assay measures CK-MB activity concentration; the Magic Lite assay measures CK-MB mass concentration.
While patient correlations were excellent, the absolute results differ by approximately twofold (the value for BD activity was -50% of that for Magic Lite mass). However, both activity and mass measurements of CK-MB have been used in clinical laboratories and are accepted by clinicians. It should be important for manufacturers, during the future development of monoclonal anti-CK-MB antibody based CK-MB assays, to agree on the standardization of these assays to avoid nonuniformity within activity-and (or) mass-concentration results. This was apparent during comparisons with electrophoretically derived results. Compared with electrophoresis, both immunoassays eliminated the problem of falsely negative CK-MB results. Electrophoresis was limited by its lower limit of detection (5-10 U/L) as well as when high total-CK activities were present. Samples with high total-CK activities often must be diluted for proper resolution and linear densitometry of the gels, and this often results in no CK-MB being detected. Large dilutions cause even larger errors when final results are calculated after multiplication of small numbers. As shown in Figure 2 , correlation between BD activity and electrophoretic activity was good, but CK-MB activity appeared to be overestimated by electrophoresis. However, as mentioned earlier, standardization between assays was not uniform. Since this premarketing trial of the BD CK-MB assay, the manufacturer has increased its washing procedure from two 2-mL washes to three 3-mL washes, which it claims eliminates any potential CK-MM carryover when high total CK activities (>3000 U/L) are encountered during the CK-MB measurement.
Occasionally we obtained results for sample duplicates that showed poor precision, >10% CV in both assays. This occurred at all CK-MB concentrations and required reanalysis of the samples. Also, the sample sizes of 0.4 mL in the BD assay and 0.2 mL in the Magic Lite assay (total volume for duplicates) might present a problem for sampling from the pediatric population. Finally, the calibration of the Magic Lite assay, as confirmed by the manufacturer, was temperature dependent. Additional studies will need to address this issue regarding variability of patients' results during the course of a run with changes in ambient temperature over time.
In conclusion, we were extremely pleased with the analytical and clinical performance of both monoclonal anti-CK-MB antibody-based immunoassays.
We plan to replace our current clinical laboratory's electrophoresis measurement of CK-MB with one of the new anti-CK-MB antibody-based immunoassays.
The problem of not being able to observe CK-BB, nutochondrial-CK, and macro-CK by electrophoresis will be overcome with the increased sensitivity and specificity of these newer assays. systems greatly depend on positioning the film element so that the reflectance measurement is taken across the middle of both spots. In both cases the film element was removed from its plastic support. In the current design, I use a square photodiode array and an automated slide-transport mechanism with an incubator. Software algorithms are used to locate the spot, which greatly relaxes the requirements for exact sample positioning. I compute each sample volume based on spot area and provide a computed correction to compensate for small variations in sample size. By using a 37#{176}C incubator I have been able to extend the time between calibrations.
MaterIals and Methods
Instrument.
A photograph of the instrument is shown in Figure 1 . I used a slide-transport assembly and incubator from an Ektachem DT6O analyzer (Eastman Kodak Co., Rochester, NY). Two additional optical limit switches were added to aid in monitoring the position of the slide transport mechanism. The stepping motor for the slide transport mechanism was controlled by the compuer via a 16-bit 110 Fig. 1 . Photograph of the instrument, with partial removal of panelsto show internal components
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